Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT00968968
Title Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Recruitment Terminated
Gender female
Phase Phase III
Variant Requirements No
Sponsors GlaxoSmithKline
Indications

breast cancer

Therapies

Trastuzumab

Lapatinib + Trastuzumab

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.